8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Feb 24, 2026·SEC
Edesa Biotech, Inc.(EDSA)Earnings, Financials & Key Ratios
EDSA•NASDAQ
Price updated Jun 11, 2026
AboutEdesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.Show more
- Revenue$0
- EBITDA-$8M-14.1%
- Net Income-$7M-16.5%
- EPS (Diluted)-1.27+34.2%
- ROE-99.57%+27.1%
- ROIC-452.35%-18.0%
EDSA Key Insights
Edesa Biotech, Inc. (EDSA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 77.5% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EDSA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EDSA Price & Volume
Edesa Biotech, Inc. (EDSA) stock price & volume — 10-year historical chart
Loading chart...
EDSA Growth Metrics
Edesa Biotech, Inc. (EDSA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-78.9%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.63%
Return on Capital
10 Years-102.94%
5 Years-150.22%
3 Years-125.47%
Last Year-109.63%
EDSA Recent Earnings
Edesa Biotech, Inc. (EDSA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 14, 2026EPS
$0.49
Est $0.24
-104.2%
Revenue
$50,918
Est $50,918
+0.0%
Q1 2026
Feb 13, 2026EPS
$0.28
Est $0.28
+0.0%
Revenue
—
Q4 2025
Dec 12, 2025EPS
$0.32
Est $0.27
-18.5%
Revenue
—
Q3 2025
Aug 8, 2025EPS
$0.25
Est $0.26
+3.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 14, 2026 | $0.49vs $0.24-104.2% | $50,918vs $50,918+0.0% |
| Q1 2026 | Feb 13, 2026 | $0.28vs $0.28+0.0% | — |
| Q4 2025 | Dec 12, 2025 | $0.32vs $0.27-18.5% | — |
| Q3 2025 | Aug 8, 2025 | $0.25vs $0.26+3.8% | — |
Based on last 12 quarters of dataView full earnings history →
EDSA Peer Comparison
Edesa Biotech, Inc. (EDSA) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ADMA | 1.93B | 8.32 | 13.87 | 19.63% | 32.43% | 38.97% | 0.17 | |
 NUVB | 1.65B | 4.76 | -7.93 | 6.99% | -102.06% | -44.1% | 0.03 | |
 HALO | 8.39B | 70.73 | 27.63 | 37.55% | 23.13% | 126.27% | 43.89 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 ARQT | 3.08B | 24.59 | -189.15 | 91.34% | -0.57% | -1.41% | 0.03 | |
 SLDB | 562.51M | 7.22 | -3.63 | -74.45% | 0.12 | |||
 VYNE | 28.44M | 0.66 | -1.07 | 13.77% | -47.26% | -69.57% |
Compare EDSA vs Peers
Edesa Biotech, Inc. (EDSA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EDSA Income Statement
Edesa Biotech, Inc. (EDSA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 228.29K | 211.85K | 410.87K | 328.8K | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | -82.05% | -7.2% | 93.94% | -19.97% | -100% | - | - | - | - | - |
Cost of Goods Sold | 534.45K | 445.32K | 101.29K | 17.6K | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K | 77.2K |
COGS % of Revenue | 234.11% | 210.21% | 24.65% | 5.35% | - | - | - | - | - | - |
Gross Profit | -306.17K▲ 0% | -233.47K▲ 23.7% | 309.58K▲ 232.6% | 311.2K▲ 0.5% | -118.79K▼ 138.2% | -118.19K▲ 0.5% | -183.47K▼ 55.2% | -186.05K▼ 1.4% | -119.27K▲ 35.9% | -77.2K▲ 0% |
Gross Margin % | -134.11% | -110.21% | 75.35% | 94.65% | - | - | - | - | - | - |
Gross Profit Growth % | -312.82% | 23.74% | 232.6% | 0.52% | -138.17% | 0.51% | -55.24% | -1.41% | 35.89% | - |
Operating Expenses | 4.92M | 4.84M | 3.14M | 6.71M | 23.68M | 18.37M | 9.22M | 7.01M | 7.79M | 10.94M |
OpEx % of Revenue | 2154.47% | 2286.9% | 764.65% | 2041.37% | - | - | - | - | - | - |
Selling, General & Admin | 2.94M | 2.76M | 2.05M | 3.38M | 5.73M | 5.04M | 4.43M | 4.13M | 4.24M | 4.96M |
SG&A % of Revenue | 1290.03% | 1301.58% | 497.8% | 1028.77% | - | - | - | - | - | - |
Research & Development | 1.97M | 2.09M | 1.1M | 3.33M | 17.95M | 13.34M | 4.79M | 2.88M | 3.67M | 6.06M |
R&D % of Revenue | 864.44% | 985.33% | 266.85% | 1012.6% | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -119.27K | -77.2K |
Operating Income | -5.22M▲ 0% | -5.08M▲ 2.8% | -2.83M▲ 44.2% | -6.4M▼ 126.0% | -23.68M▼ 270.0% | -18.37M▲ 22.4% | -9.22M▲ 49.8% | -7.01M▲ 23.9% | -7.91M▼ 12.8% | -11.01M▲ 0% |
Operating Margin % | -2288.59% | -2397.11% | -689.3% | -1946.72% | - | - | - | - | - | - |
Operating Income Growth % | -6.44% | 2.8% | 44.23% | -126.01% | -269.97% | 22.43% | 49.8% | 23.94% | -12.78% | - |
EBITDA | -5.05M | -4.89M | -2.83M | -6.34M | -23.56M | -18.25M | -9.04M | -6.83M | -7.79M | -10.91M |
EBITDA Margin % | -2210.04% | -2308.19% | -687.75% | -1929.22% | - | - | - | - | - | - |
EBITDA Growth % | -6.02% | 3.08% | 42.21% | -124.48% | -271.46% | 22.54% | 50.48% | 24.46% | -14.11% | -72.86% |
D&A (Non-Cash Add-back) | 179.32K | 188.37K | 6.37K | 57.56K | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K | 102.99K |
EBIT | -5.03M | -5.04M | -2.83M | -6.4M | -13.34M | -17.55M | -8.37M | -6.17M | -7.18M | -10.58M |
Net Interest Income | 0 | 0 | 56.84K | 37.78K | 11.16K | 64 | 289.85K | 153.5K | 2.56K | 1.31K |
Interest Income | 0 | 0 | 56.84K | 37.78K | 11.16K | 64 | 289.85K | 153.5K | 2.56K | 1.31K |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 194.7K | 40.1K | -309.44K | 37.41K | 10.34M | 822.67K | 849.14K | 845.5K | 726.84K | 569.35K |
Pretax Income | -5.03M▲ 0% | -5.04M▼ 0.2% | -2.78M▲ 44.9% | -6.36M▼ 129.2% | -13.34M▼ 109.7% | -17.55M▼ 31.5% | -8.37M▲ 52.3% | -6.17M▲ 26.3% | -7.18M▼ 16.5% | -10.44M▲ 0% |
Pretax Margin % | -2203.3% | -2378.18% | -675.82% | -1935.34% | - | - | - | - | - | - |
Income Tax | 800 | 800 | -55.4K | 800 | 800 | 800 | 800 | 800 | 800 | 800 |
Effective Tax Rate % | -0.02% | -0.02% | 2% | -0.01% | -0.01% | -0% | -0.01% | -0.01% | -0.01% | -0.01% |
Net Income | -5.03M▲ 0% | -5.04M▼ 0.2% | -2.72M▲ 46.0% | -6.36M▼ 133.9% | -13.34M▼ 109.7% | -17.55M▼ 31.5% | -8.37M▲ 52.3% | -6.17M▲ 26.3% | -7.19M▼ 16.5% | -10.44M▲ 0% |
Net Margin % | -2203.65% | -2378.56% | -662.33% | -1935.59% | - | - | - | - | - | - |
Net Income Growth % | -0.09% | -0.17% | 45.99% | -133.86% | -109.66% | -31.52% | 52.28% | 26.32% | -16.46% | -78.9% |
Net Income (Continuing) | -5.03M | -5.04M | -3.14M | -6.36M | -13.34M | -17.55M | -8.37M | -6.17M | -7.19M | -10.44M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -211.28▲ 0% | -10.54▲ 95.0% | -4.15▲ 60.6% | -5.18▼ 24.8% | -7.73▼ 49.2% | -8.37▼ 8.3% | -2.93▲ 65.0% | -1.93▲ 34.1% | -1.27▲ 34.2% | -1.27▲ 0% |
EPS Growth % | -783.28% | 95.01% | 60.63% | -24.82% | -49.23% | -8.28% | 64.99% | 34.13% | 34.2% | 15.63% |
EPS (Basic) | -218.72 | -10.54 | -4.15 | -5.18 | -7.74 | -8.37 | -2.93 | -1.93 | -1.27 | - |
Diluted Shares Outstanding | 23.81K | 478.23K | 655.32K | 1.23M | 1.73M | 2.1M | 2.86M | 3.2M | 5.68M | 8.25M |
Basic Shares Outstanding | 23K | 478.23K | 655K | 1.23M | 1.73M | 2.1M | 2.86M | 3.2M | 5.68M | 8.25M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
EDSA Balance Sheet
Edesa Biotech, Inc. (EDSA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 6.76M | 10.66M | 5.64M | 8.1M | 12.09M | 9.09M | 6.44M | 1.68M | 11.51M | 10.42M |
Cash & Short-Term Investments | 6.57M | 10.3M | 5.03M | 7.21M | 7.84M | 7.09M | 5.36M | 1.04M | 10.79M | 10M |
Cash Only | 4.57M | 4.23M | 5.03M | 7.21M | 7.84M | 7.09M | 5.36M | 1.04M | 10.79M | 10M |
Short-Term Investments | 1.99M | 6.08M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.29K | 41.25K | 217.1K | 87.45K | 3.3M | 1.26M | 626.54K | 270.91K | 642.87K | 216.47K |
Days Sales Outstanding | 2.06 | 71.06 | 192.86 | 97.07 | - | - | - | - | - | - |
Inventory | 68.11K | 224.27K | -217.1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 46.52 | 183.82 | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 86.92K | 0 | 0 | 0 | 0 | 448.91K | 367.39K | 77.84K | 197.58K |
Total Non-Current Assets | 961.56K | 1.12M | 73.06K | 2.66M | 2.49M | 2.48M | 2.45M | 2.14M | 2.02M | 1.97M |
Property, Plant & Equipment | 879.52K | 1.06M | 73.06K | 174.82K | 111.56K | 31.16K | 100.08K | 18.36K | 0 | 0 |
Fixed Asset Turnover | 0.26x | 0.20x | 5.62x | 1.88x | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 2.48M | 2.38M | 2.28M | 2.18M | 2.08M | 1.98M | 1.93M |
Long-Term Investments | 66.69K | 46.46K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 15.34K | 15.34K | 0 | 0 | 0 | 171.46K | 173.49K | 41.15K | 39.97K | 39.92K |
Total Assets | 7.72M▲ 0% | 11.78M▲ 52.6% | 5.72M▼ 51.5% | 10.76M▲ 88.2% | 14.58M▲ 35.5% | 11.58M▼ 20.6% | 8.89M▼ 23.2% | 3.81M▼ 57.1% | 13.53M▲ 254.8% | 12.38M▲ 0% |
Asset Turnover | 0.03x | 0.02x | 0.07x | 0.03x | - | - | - | - | - | 0.00x |
Asset Growth % | -40.33% | 52.59% | -51.46% | 88.23% | 35.52% | -20.63% | -23.2% | -57.1% | 254.76% | 669.92% |
Total Current Liabilities | 320.95K | 493.38K | 461.63K | 1.53M | 1.46M | 2.14M | 1.82M | 1.83M | 1.08M | 2.19M |
Accounts Payable | 320.95K | 493.38K | 424.63K | 1.46M | 1.38M | 2.12M | 1.75M | 1.81M | 0 | 0 |
Days Payables Outstanding | 219.19 | 404.4 | 1.53K | 30.28K | 4.24K | 6.55K | 3.48K | 3.56K | - | 795.11 |
Short-Term Debt | 0 | 0 | 0 | 69.73K | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | -1.46K | 0 | -2.12M | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | -68.27K | 0 | 2.12M | 0 | 0 | 1.08M | 2.19M |
Current Ratio | 21.06x | 21.60x | 12.23x | 5.30x | 8.29x | 4.25x | 3.53x | 0.91x | 10.67x | 4.76x |
Quick Ratio | 20.85x | 21.14x | 12.70x | 5.30x | 8.29x | 4.25x | 3.53x | 0.91x | 10.67x | 4.76x |
Cash Conversion Cycle | -170.61 | -149.51 | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 0 | 2.6M | 67.71K | 43.66K | 19.77K | 126K | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 94.46K | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 94.46K | 20.51K | 0 | 19.77K | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 126K | 0 | 131K |
Other Non-Current Liabilities | 0 | 0 | 0 | 2.41M | 47.2K | 43.66K | 0 | 0 | 0 | 0 |
Total Liabilities | 320.95K | 493.38K | 461.63K | 4.13M | 1.53M | 2.18M | 1.84M | 1.83M | 1.08M | 2.19M |
Total Debt | 0 | 0 | 0 | 164.19K | 99.32K | 18.98K | 94.49K | 19.87K | 0 | 0 |
Net Debt | -4.57M | -4.23M | -5.03M | -7.05M | -7.74M | -7.07M | -5.27M | -1.02M | -10.79M | -10M |
Debt / Equity | - | - | - | 0.02x | 0.01x | 0.00x | 0.01x | 0.01x | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.92x |
Interest Coverage | - | - | - | - | - | - | - | - | - | - |
Total Equity | 7.4M▲ 0% | 11.29M▲ 52.5% | 5.26M▼ 53.4% | 6.63M▲ 26.2% | 13.06M▲ 96.9% | 9.39M▼ 28.1% | 7.05M▼ 24.9% | 1.98M▼ 71.9% | 12.45M▲ 528.5% | 10.2M▲ 0% |
Equity Growth % | -39.91% | 52.54% | -53.43% | 26.16% | 96.92% | -28.08% | -24.94% | -71.89% | 528.52% | 1403.41% |
Book Value per Share | 310.75 | 23.60 | 8.02 | 5.39 | 7.57 | 4.48 | 2.47 | 0.62 | 2.19 | 1.24 |
Total Shareholders' Equity | 7.4M | 11.29M | 5.26M | 6.63M | 13.06M | 9.39M | 7.05M | 1.98M | 12.45M | 10.2M |
Common Stock | 48.35M | 56.65M | 12.01M | 18.5M | 34.89M | 42.47M | 46.64M | 47.24M | 54.52M | 58.93M |
Retained Earnings | -45.39M | -50.43M | -6.73M | -13.13M | -26.5M | -44.04M | -52.42M | -58.59M | -65.91M | -72.45M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 4.44M | 5.06M | -342.07K | -287.2K | -205.26K | -213.6K | -214.65K | -242.61K | -165.77K | -186.09K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EDSA Cash Flow Statement
Edesa Biotech, Inc. (EDSA) cash flow — operating, investing & free cash flow history
| Metric | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -4.7M | -4.62M | -4.85M | -4.99M | -13.66M | -12.28M | -6.64M | -4.89M | -7.32M | -7.65M |
Operating CF Margin % | -2058.66% | -2178.68% | -1179.4% | -1516.52% | - | - | - | - | - | - |
Operating CF Growth % | -4.31% | 1.79% | -4.99% | -2.9% | -174.05% | 10.14% | 45.95% | 26.31% | -49.73% | -212.5% |
Net Income | -5.03M | -5.04M | -2.78M | -6.36M | -13.34M | -17.55M | -8.37M | -6.17M | -7.19M | -10.44M |
Depreciation & Amortization | 179.32K | 188.37K | 4.78K | 57.56K | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K | 120.64K |
Stock-Based Compensation | 115.55K | 154.31K | 46.51K | 598.36K | 3.2M | 2.26M | 1.25M | 537.49K | 729.64K | 662.99K |
Deferred Taxes | 0 | 55.3K | -2.76M | -655.92K | -3.31M | -2.38M | -308K | 0 | 0 | 0 |
Other Non-Cash Items | -162.03K | 12.42K | 2.75M | 655.92K | 3.31M | 2.38M | 308K | -14.77K | 0 | -247.18K |
Working Capital Changes | 198.16K | 13.04K | -2.11M | 721.97K | -3.64M | 2.89M | 308K | 571.07K | -985.65K | 1.62M |
Change in Receivables | 84.57K | -40K | 9.74K | 127.13K | -3.23M | 2.03B | 562.77K | 356.34K | -377.99K | 182.9K |
Change in Inventory | 181.32K | -156.15K | 77.91K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -302.73K | 172.45K | -1.88M | 998.9K | -124.72K | 882.84K | -556.27K | 0 | 0 | 0 |
Cash from Investing | 1.69M | -4.47M | 6.42M | 19.07K | -6.15K | -5.66K | 0 | 0 | 0 | 0 |
Capital Expenditures | -302.73K | -382.81K | -8.1K | -34.34K | -6.15K | -5.66K | 3 | 0 | 0 | 0 |
CapEx % of Revenue | 132.61% | 180.7% | 1.97% | 10.44% | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 6.39M | 29.48K | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 36.74K | 23.93K | 0 | 0 | -3 | 0 | 0 | 0 |
Cash from Financing | 5.91K | 8.77M | 0 | 7.09M | 14.17M | 11.63M | 4.83M | 592.03K | 17.03M | 3.84M |
Debt Issued (Net) | 0 | 0 | 0 | 29.75K | 0 | 0 | 0 | -29.53K | 0 | 23.14K |
Equity Issued (Net) | 0 | 8.77M | 0 | 7.06M | 14.17M | 11.63M | 4.83M | 621.56K | 17.03M | 4.01M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 5.91K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -201.78K |
Net Change in Cash | -2.85M▲ 0% | -345.43K▲ 87.9% | 1.66M▲ 581.6% | 2.18M▲ 31.2% | 625.56K▼ 71.3% | -748.34K▼ 219.6% | -1.73M▼ 131.1% | -4.32M▼ 150.0% | 9.75M▲ 325.6% | -3.89M▲ 0% |
Free Cash Flow | -5M▲ 0% | -5M▲ 0.1% | -4.85M▲ 2.9% | -5.02M▼ 3.4% | -13.67M▼ 172.3% | -12.28M▲ 10.1% | -6.64M▲ 46.0% | -4.89M▲ 26.3% | -7.32M▼ 49.7% | -7.65M▲ 0% |
FCF Margin % | -2191.27% | -2359.38% | -1181.37% | -1526.97% | - | - | - | - | - | - |
FCF Growth % | -1.93% | 0.08% | 2.89% | -3.44% | -172.3% | 10.14% | 45.98% | 26.31% | -49.73% | -34.92% |
FCF per Share | -210.10 | -10.45 | -7.41 | -4.08 | -7.92 | -5.86 | -2.32 | -1.53 | -1.29 | -0.93 |
FCF Conversion (FCF/Net Income) | 0.93x | 0.92x | 1.78x | 0.78x | 1.02x | 0.70x | 0.79x | 0.79x | 1.02x | 0.73x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 800 | 800 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EDSA Key Ratios
Edesa Biotech, Inc. (EDSA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -51.04% | -53.93% | -32.9% | -107.08% | -135.54% | -156.34% | -101.88% | -136.66% | -99.57% | -82.34% |
| Return on Invested Capital (ROIC) | -101.44% | -77.03% | -58.3% | - | -724.94% | -360.79% | -337.32% | -383.24% | -452.35% | -597.86% |
| Gross Margin | -134.11% | -110.21% | 75.35% | 94.65% | - | - | - | - | - | - |
| Net Margin | -2203.65% | -2378.56% | -662.33% | -1935.59% | - | - | - | - | - | - |
| Debt / Equity | - | - | - | 0.02x | 0.01x | 0.00x | 0.01x | 0.01x | - | 0.00x |
| FCF Conversion | 0.93x | 0.92x | 1.78x | 0.78x | 1.02x | 0.70x | 0.79x | 0.79x | 1.02x | 0.73x |
| Revenue Growth | -82.05% | -7.2% | 93.94% | -19.97% | -100% | - | - | - | - | - |
Related:EDSA Dividend History·EDSA Revenue History·EDSA Price History·EDSA P/E History·EDSA Financial Ratios·EDSA Institutional Holders
EDSA SEC Filings & Documents
Edesa Biotech, Inc. (EDSA) SEC filings — annual & quarterly reports (10-K, 10-Q)
EDSA Frequently Asked Questions
Edesa Biotech, Inc. (EDSA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Edesa Biotech, Inc. (EDSA) grew revenue by 0.0% over the past year. Growth has been modest.
Edesa Biotech, Inc. (EDSA) reported a net loss of $10.4M for fiscal year 2025.
Dividend & Returns
Edesa Biotech, Inc. (EDSA) has a return on equity (ROE) of -99.6%. Negative ROE indicates the company is unprofitable.
Edesa Biotech, Inc. (EDSA) had negative free cash flow of $7.7M in fiscal year 2025, likely due to heavy capital investments.